309 related articles for article (PubMed ID: 9594935)
1. Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison.
Hazen KC
J Am Acad Dermatol; 1998 May; 38(5 Pt 3):S37-41. PubMed ID: 9594935
[TBL] [Abstract][Full Text] [Related]
2. Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis.
Carrillo-Muñoz AJ; Giusiano G; Cárdenes D; Hernández-Molina JM; Eraso E; Quindós G; Guardia C; del Valle O; Tur-Tur C; Guarro J
Int J Antimicrob Agents; 2008 Jun; 31(6):540-3. PubMed ID: 18367383
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity.
Gupta AK; Kohli Y
Br J Dermatol; 2003 Aug; 149(2):296-305. PubMed ID: 12932235
[TBL] [Abstract][Full Text] [Related]
5. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses.
Clayton YM
Br J Dermatol; 1994 Apr; 130 Suppl 43():7-8. PubMed ID: 8186143
[TBL] [Abstract][Full Text] [Related]
6. Terbinafine: a review of its use in onychomycosis in adults.
Darkes MJ; Scott LJ; Goa KL
Am J Clin Dermatol; 2003; 4(1):39-65. PubMed ID: 12477372
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species.
Gupta AK; Kohli Y; Batra R
Med Mycol; 2005 Mar; 43(2):179-85. PubMed ID: 15832561
[TBL] [Abstract][Full Text] [Related]
8. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.
Sarifakioglu E; Seçkin D; Demirbilek M; Can F
Clin Exp Dermatol; 2007 Nov; 32(6):675-9. PubMed ID: 17714532
[TBL] [Abstract][Full Text] [Related]
9. Determination of minimum inhibitory concentrations of itraconazole, terbinafine and ketoconazole against dermatophyte species by broth microdilution method.
Bhatia VK; Sharma PC
Indian J Med Microbiol; 2015; 33(4):533-7. PubMed ID: 26470960
[TBL] [Abstract][Full Text] [Related]
10. Effect of Lamisil and azole antifungals in experimental nail infection.
Richardson MD
Dermatology; 1997; 194 Suppl 1():27-31. PubMed ID: 9154398
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes.
Simonetti O; Silvestri C; Arzeni D; Cirioni O; Kamysz W; Conte I; Staffolani S; Orsetti E; Morciano A; Castelli P; Scalise A; Kamysz E; Offidani AM; Giacometti A; Barchiesi F
Mycoses; 2014 Apr; 57(4):233-9. PubMed ID: 26058322
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacology of terbinafine and itraconazole.
Leyden J
J Am Acad Dermatol; 1998 May; 38(5 Pt 3):S42-7. PubMed ID: 9594936
[TBL] [Abstract][Full Text] [Related]
13. In vitro comparison of terbinafine and itraconazole against Penicillium marneffei.
McGinnis MR; Nordoff NG; Ryder NS; Nunn GB
Antimicrob Agents Chemother; 2000 May; 44(5):1407-8. PubMed ID: 10770792
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial effect of fluconazole, itraconazole, and terbinafine with different culture extracts of Candida parapsilosis and Trichophyton spp. against Trichophyton rubrum.
Lemes TH; Nascentes JAS; Regasini LO; Siqueira JPZ; Maschio-Lima T; Pattini VC; Ribeiro MD; de Almeida BG; de Almeida MTG
Int Microbiol; 2024 Jun; 27(3):899-905. PubMed ID: 37875749
[TBL] [Abstract][Full Text] [Related]
15. Antifungal activity of the allylamine derivative terbinafine in vitro.
Petranyi G; Meingassner JG; Mieth H
Antimicrob Agents Chemother; 1987 Sep; 31(9):1365-8. PubMed ID: 3674847
[TBL] [Abstract][Full Text] [Related]
16. [In vitro antifungal activity of ravuconazole against isolates of dermatophytes and Candida species from patients with dermatomycoses].
Yamaguchi H; Ikeda F; Iyoda T; Suzuki M; Mikawa T
Med Mycol J; 2014; 55(4):J157-63. PubMed ID: 25742996
[TBL] [Abstract][Full Text] [Related]
17. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day.
De Backer M; De Vroey C; Lesaffre E; Scheys I; De Keyser P
J Am Acad Dermatol; 1998 May; 38(5 Pt 3):S57-63. PubMed ID: 9594939
[TBL] [Abstract][Full Text] [Related]
18. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Jo Siu WJ; Tatsumi Y; Senda H; Pillai R; Nakamura T; Sone D; Fothergill A
Antimicrob Agents Chemother; 2013 Apr; 57(4):1610-6. PubMed ID: 23318803
[TBL] [Abstract][Full Text] [Related]
19. In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes.
Ghannoum M; Isham N; Long L
Antimicrob Agents Chemother; 2015 Sep; 59(9):5154-8. PubMed ID: 26055386
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey.
Oz Y; Qoraan I; Oz A; Balta I
Int J Dermatol; 2017 Jan; 56(1):68-74. PubMed ID: 27667305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
